Cellebrite DI (CLBT) Expected to Announce Earnings on Wednesday

Cellebrite DI (NASDAQ:CLBT) will likely be announcing its Q4 2025 results before the market opens on Wednesday, February 11th. Analysts expect the company to announce earnings of $0.14 per share and revenue of $126.0740 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, February 11, 2026 at 8:30 AM ET.

Cellebrite DI (NASDAQ:CLBT) last issued its earnings results on Wednesday, November 12th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.05). Cellebrite DI had a net margin of 16.74% and a return on equity of 20.81%. The firm had revenue of $126.03 million during the quarter, compared to analysts’ expectations of $122.98 million. During the same quarter in the prior year, the company earned $0.14 EPS. Cellebrite DI’s quarterly revenue was up 17.9% on a year-over-year basis. On average, analysts expect Cellebrite DI to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cellebrite DI Trading Down 4.2%

Shares of NASDAQ:CLBT opened at $14.28 on Wednesday. Cellebrite DI has a twelve month low of $13.10 and a twelve month high of $26.30. The company has a market cap of $3.42 billion, a PE ratio of 46.06, a price-to-earnings-growth ratio of 2.08 and a beta of 1.28. The company’s 50 day moving average is $17.57 and its 200 day moving average is $17.03.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Invesco Ltd. raised its holdings in Cellebrite DI by 58.6% in the 3rd quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock valued at $103,030,000 after acquiring an additional 2,054,644 shares during the last quarter. Cooper Creek Partners Management LLC acquired a new position in Cellebrite DI during the third quarter worth $55,999,000. Nine Ten Capital Management LLC grew its stake in shares of Cellebrite DI by 16.9% in the third quarter. Nine Ten Capital Management LLC now owns 2,479,727 shares of the company’s stock valued at $45,949,000 after buying an additional 358,193 shares in the last quarter. Ashford Capital Management Inc. boosted its holdings in Cellebrite DI by 34.3% during the 3rd quarter. Ashford Capital Management Inc. now owns 1,700,285 shares of the company’s stock valued at $31,506,000 after acquiring an additional 434,615 shares during the period. Finally, Qube Research & Technologies Ltd grew its position in Cellebrite DI by 93.7% in the 2nd quarter. Qube Research & Technologies Ltd now owns 1,500,505 shares of the company’s stock valued at $24,008,000 after acquiring an additional 725,679 shares in the last quarter. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Cellebrite DI in a report on Monday, December 29th. Needham & Company LLC increased their price target on Cellebrite DI from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Wall Street Zen cut Cellebrite DI from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Lake Street Capital upped their target price on Cellebrite DI from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Finally, Bank of America lifted their price target on Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $24.00.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.